8-K: Ocuphire Pharma Engages Director as Consultant with Stock Awards

Ocuphire Pharma has entered into a consulting agreement with board member Jay Pepose, M.D., providing monthly fees, restricted stock units, and stock options.

Summary

• Ocuphire Pharma has engaged Jay Pepose, M.D., a member of their board of directors, as a consultant.
• The consulting agreement, effective April 11, 2024, includes a monthly fee of $39,583.00.
• Dr. Pepose will also receive 32,000 restricted stock units (RSUs) that vest on April 11, 2025.
• Additionally, he will be granted stock options to purchase 48,000 shares, vesting in 12 monthly installments starting May 11, 2024.
• The options exercise price is based on the closing stock price of $1.79 on April 11, 2024.
• The consulting agreement is set to terminate on April 11, 2025, unless both parties agree to extend it.
• Dr. Pepose will provide consulting services in the field of ophthalmology, advising on clinical strategy, study design, and regulatory matters.

Sentiment

Score: 7

Explanation: The document outlines a standard business agreement with a positive outlook due to the engagement of a key expert, but with some potential risks related to costs and equity dilution.

Positives

• Engaging a board member as a consultant provides continuity and leverages existing knowledge of the company.
• The consulting agreement provides a clear structure for compensation and services.
• The vesting schedule for RSUs and stock options incentivizes continued service and alignment with company goals.
• Dr. Pepose's expertise in ophthalmology is expected to benefit the company's clinical and regulatory efforts.

Negatives

• The consulting agreement represents an additional expense for the company.
• The vesting of RSUs and stock options could potentially dilute existing shareholders if not managed carefully.
• The agreement's termination date of April 11, 2025, introduces uncertainty about the long-term availability of Dr. Pepose's services.

Risks

• The consulting agreement could be terminated early due to breach of contract or other specified events.
• The company is reliant on Dr. Pepose's continued service for the vesting of his equity awards.
• There is a risk that the consulting services may not meet the company's expectations or deliver the desired results.
• The company may face challenges in managing the potential conflicts of interest arising from Dr. Pepose's dual role as a board member and consultant.

Future Outlook

The consulting agreement is set to terminate on April 11, 2025, unless both parties mutually agree to extend it, indicating a potential need for renegotiation or a new agreement in the future.

Management Comments

• The document includes a signature from Dr. George Magrath, Chief Executive Officer, indicating his approval of the agreement.

Industry Context

The engagement of a key opinion leader (KOL) as a consultant is a common practice in the pharmaceutical industry, particularly in specialized fields like ophthalmology, to leverage their expertise in clinical development and regulatory strategy.

Comparison to Industry Standards

• Consulting agreements with board members are not uncommon in the biotech industry, especially when the individual has specific expertise relevant to the company's goals.
• The compensation structure, including a mix of cash fees and equity awards, is typical for consulting arrangements with experienced professionals.
• The vesting schedule for equity awards is designed to align the consultant's interests with the company's long-term success, which is a standard practice.
• The specific terms of the agreement, such as the monthly fee and the number of equity awards, would need to be compared to similar agreements in the industry to assess their competitiveness.

Related Party Transactions

• The consulting agreement is a related party transaction as Dr. Pepose is a member of the board of directors.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the equity awards.
• Employees may benefit from the expertise of Dr. Pepose.
• The company's clinical and regulatory efforts may be positively impacted by the consulting services.

Next Steps

• Dr. Pepose will begin providing consulting services in ophthalmology.
• The company will monitor the performance of the consulting agreement and the vesting of equity awards.
• The company and Dr. Pepose will need to decide whether to extend the agreement before its termination date on April 11, 2025.

Key Dates

Keywords

consulting agreement, ophthalmology, restricted stock units, stock options, clinical strategy, regulatory matters, board member, Jay Pepose, Ocuphire Pharma